Clinical Significance of FOXP3 Expression in BRCA1/2-Mutant Breast Cancer
10.3971/j.issn.1000-8578.2024.24.0134
- VernacularTitle:FOXP3在BRCA1/2突变乳腺癌中的表达及临床意义
- Author:
Linxi CHEN
1
;
Li HU
1
;
Jiuan CHEN
1
;
Lu YAO
1
;
Juan ZHANG
1
;
Ye XU
1
;
Yuntao XIE
1
Author Information
1. Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
- Publication Type:CLINICALRESEARCH
- Keywords:
BRCA1/2 mutation;
Breast cancer;
FOXP3;
Homologous recombination deficiency
- From:
Cancer Research on Prevention and Treatment
2024;51(7):561-566
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the potential significance of FOXP3 expression in BRCA1/2-mutant breast cancer. Methods A total of 48 BRCA mutation carriers (16 with BRCA1 and 32 with BRCA2) and 78 age-matched non-carriers were included in this study. Immunohistochemistry was used to detect the expression of FOXP3 in breast cancer tissues. The FOXP3 RNA expression in 39 BRCA1, 36 BRCA2, and 948 non-carrier breast cancer patients from TCGA-BRCA and the correlation with homologous recombination deficiency scores were evaluated to validate the immunohistochemistry results. Results The FOXP3 positive rate was 43.8% (7/16) in BRCA1 mutation carriers, 59.4% (19/32) in BRCA2 mutation carriers, and 9.0% (7/78) in non-carriers. The FOXP3 positive rates in patients with BRCA1/2 mutant breast cancer were significantly higher than those in non-carriers (P=0.002; P<0.001). TCGA-BRCA results showed that the FOXP3 RNA level in BRCA1/2 mutant breast cancer was significantly higher than that in non-carriers (P=0.02, P=0.004). The FOXP3 RNA level was positively correlated with the homologous recombination deficiency score (Spearman R=0.30, P<2.2e-16). Conclusion Patients with BRCA1/2 mutant breast cancers have higher FOXP3 expression than non-carriers, and may be more sensitive to immunotherapy.
